We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now?
Read MoreHide Full Article
Key Takeaways
BSX is gaining from international expansion, MedSurg market-share gains and strong WATCHMAN performance.
BSX saw emerging-market net sales rise 11.5% and APAC sales climb 16.9% operationally in Q3 2025.
BSX's WATCHMAN franchise grew 35% in Q3, with more than 600,000 patients treated globally to date.
Boston Scientific (BSX - Free Report) is well-poised to grow in the coming quarters due to its solid international expansion efforts. The company continues to gain market share across its MedSurg portfolio. In addition, BSX is thriving on the robust performance of the WATCHMAN devices worldwide. Yet, adverse macroeconomic impacts as well as operational risks from fierce competition are concerns for the company.
In the past year, this Zacks Rank #2 (Buy) stock has rallied 2.9% compared with the 3.2% fall of the industry. The S&P 500 composite has risen 19.5% in the same period.
The renowned manufacturer of medical devices and products has a market capitalization of $144.97 billion. The company’s earnings yield of 3.5% favorably compares with the industry’s 2.5% yield. BSX surpassed earnings estimates in each of the trailing four quarters, delivering an average surprise of 7.4%.
Let’s delve deeper.
Tailwinds for BSX
International Expansion Continues: Across the international regions, Boston Scientific is putting additional efforts to expand its foothold in the emerging markets (which are defined as all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada), which have strong growth potential based on their economic conditions, healthcare sectors and global capabilities. In the third quarter of 2025, emerging markets registered solid growth, with net sales increasing 11.5% operationally year over year.
Image Source: Zacks Investment Research
In Europe, the Middle East and Africa, Boston Scientific is successfully expanding its base through its diverse portfolio, new launches and commercial execution with healthy underlying market demand. In the Asia Pacific, the company registered meaningful growth across China and Japan. Sales in the region grew 16.9% operationally in the third quarter despite ongoing volume-based procurement (VBP) pressures in China. This momentum is expected to continue through the rest of 2025, supported by recent product approvals and pipeline launches such as the WATCHMAN FLX Pro device in China.
MedSurg Market Share Gain Impressive: Within Boston Scientific’s MedSurg business, the Endoscopy franchise delivered a solid performance in the third quarter, growing 9% globally and 11% in the United States, supported by strength in core platforms such as EXALT-D, MANTIS, AXIOS and OverStitch. Growth was also driven by increased procedural adoption in endoluminal surgery, including obesity and closure procedures. Meanwhile, Urology performance was led by the Stone Management and Prosthetic Urology franchises. Boston Scientific noted improving momentum for Axonics heading into 2026.
Third-quarter Neuromodulation sales grew approximately 8.6% organically, driven by strength in the deep brain stimulation (DBS) franchise, supported by the adoption of Cartesia X/HX leads and Illumina 3D programming in the United States. The Pain franchise also posted growth, led by continued strong double-digit growth in Intracept, which remains on track as the company scales adoption and continues its rollout, including progress in Europe.
WATCHMAN, a Long-Term Growth Driver: Boston Scientific’s structural heart programs are fast building momentum, banking on the strong performance of the WATCHMAN left atrial appendage closure (LAAC) device. WATCHMAN is the first device to offer a non-pharmacologic alternative to oral anticoagulants that has been studied in a randomized clinical trial and remains the leading device in percutaneous LAAC globally.
The next-generation WATCHMAN FLX and FLX Pro are strongly capturing the global market. In the third quarter of 2025, the WATCHMAN franchise grew 35%, and the device has now been used in more than 600,000 patients to date. The growth reflects accelerated concomitant uptake in the United States, strong global penetration and continued expansion into the still underserved indicated patient population. Boston Scientific continues to invest in growing the LAAC market, including enrollment of the first patient in the OPTION-A trial evaluating WATCHMAN and FARAPULSE in Asia, and anticipates initiating an IDE trial for its fourth-generation WATCHMAN device next year.
Downsides for BSX Stock
Macroeconomic Headwinds Dent Growth: Boston Scientific continues to face a challenging business environment driven by industry-wide macroeconomic pressures, including geopolitical tensions, global supply-chain disruptions and labor-market instability. International conflicts and retaliatory trade actions have increased global risks, while volatile financial markets and fluctuating prices for goods and services are squeezing profitability. The company maintains its full-year 2025 tariff impact estimate of approximately $100 million.
Competitive Landscape: The presence of a large number of players has made the medical device market highly competitive. The company participates in several markets, including Cardiovascular, CRM, Endosurgery and Neuromodulation, where it faces competition from large, well-capitalized companies such as Johnson & Johnson, Abbott, Medtronic, Stryker, Smith & Nephew and Edwards Lifesciences, apart from several other smaller companies.
BSX Stock Estimate Trend
The Zacks Consensus Estimate for Boston Scientific’s 2025 earnings per share (EPS) has increased 1 cent to $3.04 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2025 revenues is pegged at $20.1 billion. This suggests a 19.8% rise from the year-ago reported number.
Other Top MedTech Stocks
Some other top-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , BrightSpring Health Services (BTSG - Free Report) and Quest Diagnostics (DGX - Free Report) .
Phibro Animal Healthhas an earnings yield of 7.2% compared with the industry’s 2.5% yield. Shares of the company have surged 83.6% in the past year against the industry’s 3.2% fall. PAHC’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 20.8%.
BrightSpring Health Services, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 53.3% compared with the industry’s 15.5% growth. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 45.1%. BTSG shares have surged 128.1% compared with the industry’s 7.6% growth in the past year.
Quest Diagnostics, carrying a Zacks Rank #2, has an earnings yield of 6% compared with the industry’s 5.6% yield. Shares of the company have jumped 15.6% compared with the industry’s 8.3% growth. DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 2.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now?
Key Takeaways
Boston Scientific (BSX - Free Report) is well-poised to grow in the coming quarters due to its solid international expansion efforts. The company continues to gain market share across its MedSurg portfolio. In addition, BSX is thriving on the robust performance of the WATCHMAN devices worldwide. Yet, adverse macroeconomic impacts as well as operational risks from fierce competition are concerns for the company.
In the past year, this Zacks Rank #2 (Buy) stock has rallied 2.9% compared with the 3.2% fall of the industry. The S&P 500 composite has risen 19.5% in the same period.
The renowned manufacturer of medical devices and products has a market capitalization of $144.97 billion. The company’s earnings yield of 3.5% favorably compares with the industry’s 2.5% yield. BSX surpassed earnings estimates in each of the trailing four quarters, delivering an average surprise of 7.4%.
Let’s delve deeper.
Tailwinds for BSX
International Expansion Continues: Across the international regions, Boston Scientific is putting additional efforts to expand its foothold in the emerging markets (which are defined as all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada), which have strong growth potential based on their economic conditions, healthcare sectors and global capabilities. In the third quarter of 2025, emerging markets registered solid growth, with net sales increasing 11.5% operationally year over year.
Image Source: Zacks Investment Research
In Europe, the Middle East and Africa, Boston Scientific is successfully expanding its base through its diverse portfolio, new launches and commercial execution with healthy underlying market demand. In the Asia Pacific, the company registered meaningful growth across China and Japan. Sales in the region grew 16.9% operationally in the third quarter despite ongoing volume-based procurement (VBP) pressures in China. This momentum is expected to continue through the rest of 2025, supported by recent product approvals and pipeline launches such as the WATCHMAN FLX Pro device in China.
MedSurg Market Share Gain Impressive: Within Boston Scientific’s MedSurg business, the Endoscopy franchise delivered a solid performance in the third quarter, growing 9% globally and 11% in the United States, supported by strength in core platforms such as EXALT-D, MANTIS, AXIOS and OverStitch. Growth was also driven by increased procedural adoption in endoluminal surgery, including obesity and closure procedures. Meanwhile, Urology performance was led by the Stone Management and Prosthetic Urology franchises. Boston Scientific noted improving momentum for Axonics heading into 2026.
Third-quarter Neuromodulation sales grew approximately 8.6% organically, driven by strength in the deep brain stimulation (DBS) franchise, supported by the adoption of Cartesia X/HX leads and Illumina 3D programming in the United States. The Pain franchise also posted growth, led by continued strong double-digit growth in Intracept, which remains on track as the company scales adoption and continues its rollout, including progress in Europe.
WATCHMAN, a Long-Term Growth Driver: Boston Scientific’s structural heart programs are fast building momentum, banking on the strong performance of the WATCHMAN left atrial appendage closure (LAAC) device. WATCHMAN is the first device to offer a non-pharmacologic alternative to oral anticoagulants that has been studied in a randomized clinical trial and remains the leading device in percutaneous LAAC globally.
The next-generation WATCHMAN FLX and FLX Pro are strongly capturing the global market. In the third quarter of 2025, the WATCHMAN franchise grew 35%, and the device has now been used in more than 600,000 patients to date. The growth reflects accelerated concomitant uptake in the United States, strong global penetration and continued expansion into the still underserved indicated patient population. Boston Scientific continues to invest in growing the LAAC market, including enrollment of the first patient in the OPTION-A trial evaluating WATCHMAN and FARAPULSE in Asia, and anticipates initiating an IDE trial for its fourth-generation WATCHMAN device next year.
Downsides for BSX Stock
Macroeconomic Headwinds Dent Growth: Boston Scientific continues to face a challenging business environment driven by industry-wide macroeconomic pressures, including geopolitical tensions, global supply-chain disruptions and labor-market instability. International conflicts and retaliatory trade actions have increased global risks, while volatile financial markets and fluctuating prices for goods and services are squeezing profitability. The company maintains its full-year 2025 tariff impact estimate of approximately $100 million.
Competitive Landscape: The presence of a large number of players has made the medical device market highly competitive. The company participates in several markets, including Cardiovascular, CRM, Endosurgery and Neuromodulation, where it faces competition from large, well-capitalized companies such as Johnson & Johnson, Abbott, Medtronic, Stryker, Smith & Nephew and Edwards Lifesciences, apart from several other smaller companies.
BSX Stock Estimate Trend
The Zacks Consensus Estimate for Boston Scientific’s 2025 earnings per share (EPS) has increased 1 cent to $3.04 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2025 revenues is pegged at $20.1 billion. This suggests a 19.8% rise from the year-ago reported number.
Other Top MedTech Stocks
Some other top-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , BrightSpring Health Services (BTSG - Free Report) and Quest Diagnostics (DGX - Free Report) .
Phibro Animal Healthhas an earnings yield of 7.2% compared with the industry’s 2.5% yield. Shares of the company have surged 83.6% in the past year against the industry’s 3.2% fall. PAHC’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 20.8%.
PAHC carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BrightSpring Health Services, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 53.3% compared with the industry’s 15.5% growth. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 45.1%. BTSG shares have surged 128.1% compared with the industry’s 7.6% growth in the past year.
Quest Diagnostics, carrying a Zacks Rank #2, has an earnings yield of 6% compared with the industry’s 5.6% yield. Shares of the company have jumped 15.6% compared with the industry’s 8.3% growth. DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 2.5%.